Blockade of IL10 signaling promotes TLR9-driven liver dysfunction by allowing T cell receptor-mediated T cell activation
Objective Deficient IL10 signaling can contribute to macrophage activation syndrome (MAS). TLR-9 drives innate immune activation and has been used to model MAS. IL10 promotes T cell tolerance and the development of T regulatory cells. We hypothesized that in TLR-9-mediated innate immune activation, blocking IL10 would increase T cell activation and worsen MAS-associated organ dysfunction. Methods C57BL/6 mice (n=3-11/cohort) were injected with A) CpG ODN1826, a TLR9 agonist, 50μg every other day for 5 doses on days -8 — 0 (CpGLo), B) CpG 500μg on Day 0 (CpGHi), or C) CpGHi+αIL10-R blocking antibody. OTI and OTII mice, which respectively contain CD8 and CD4 cells with transgenic T cell receptors, do not respond to antigens. Wild-type C57Bl/6, OTI, and OTII mice received CpGHi+αIL10-R. Baseline (untreated) mice were included in each experiment. Animals were sacrificed one day post-challenge. Results The CpGHi cohort had lower WBC ( p< 0.0001), higher ferritin ( p = 0.0035) and higher ALT ( p< 0.05) and lower bile acid transporter mRNA levels ( p < 0.05). The CpGHi cohort had increased percentages of B cells expressing activation markers (CD80, CD86, and MHC-I, p< 0.05), of dendritic cells expressing CD86 ( p= 0.03), and of CD4 ( p< 0.0001) and CD8 ( p= 0.025) T cells expressing CD69. Compared to CpGHi, CpGHi+αIL10-R treatment increased Nur77 expression on CD4 and CD8 T cells ( p< 0.0001), did not alter innate immune cells, and was associated with worse liver function ( p< 0.05). We noted significant expansion of Nur77 + CD69 + CD8 T cells in OTI and OTII mice, indicating a TCR-associated activation leading to a CD8 T cell response. Conclusions In TLR9-induced hyperinflammation, IL10 restrained a feedforward loop of innate and T cell activation. The specificity of the innate and T cell interaction is unclear and may represent an autoimmune activation of CD8 T cells.
Authors
- Shivani Chhabra (ORCID: https://orcid.org/0000-0002-5023-3393)
- Mariana R. Brewer (ORCID: https://orcid.org/0000-0002-2614-3208)
- Matthew Eremita
- Grace M. Fisler (ORCID: https://orcid.org/0000-0001-7001-000X)
- Joyce S Hui‐Yuen (ORCID: https://orcid.org/0000-0002-0545-906X)
- Clifford Scott Deutschman (ORCID: https://orcid.org/0000-0001-9490-4024)
- Mei Qi
- Matthew D. Taylor
Institutions
- Northwell Health (US)
- Feinstein Institute for Medical Research (US)
- North Shore Diabetes and Endocrine Associates (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fimmu.2026.1941873
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Rheumatology Research Foundation
- Childhood Arthritis and Rheumatology Research Alliance
- National Institutes of Health
- National Institute of General Medical Sciences
- National Institute of Allergy and Infectious Diseases